Across TCGA pan-cancer cohorts, TM2D3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TM2D3 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TM2D3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TM2D3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, CESC, and BRCA are the cancer types where TM2D3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.667	<.001	24	view →
CESC	OS	Median	All	0.109	0.588	.007	12	view →
BRCA	OS	Median	II,III,IV	0.668	0.913	.003	10	view →
KIRP	OS	Median	All	0.192	0.705	.015	4	view →
UCEC	DFS	Median	All	1.000	0.630	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TM2D3 tumor-vs-normal RNA expression · all TM2D3 data types